Integral Health Asset Management LLC Has $2.43 Million Position in STAAR Surgical (NASDAQ:STAA)

Integral Health Asset Management LLC raised its position in STAAR Surgical (NASDAQ:STAA - Free Report) by 100.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the medical instruments supplier's stock after purchasing an additional 50,000 shares during the quarter. Integral Health Asset Management LLC owned approximately 0.20% of STAAR Surgical worth $2,429,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new position in STAAR Surgical during the fourth quarter valued at approximately $180,000. Bridgefront Capital LLC raised its holdings in shares of STAAR Surgical by 27.2% during the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock valued at $262,000 after purchasing an additional 2,306 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of STAAR Surgical in the 4th quarter valued at $278,000. Y Intercept Hong Kong Ltd bought a new position in shares of STAAR Surgical in the fourth quarter valued at approximately $292,000. Finally, Counterpoint Mutual Funds LLC acquired a new position in shares of STAAR Surgical during the fourth quarter worth approximately $298,000. 96.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on STAA shares. William Blair downgraded shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 12th. Wells Fargo & Company initiated coverage on shares of STAAR Surgical in a report on Monday, April 21st. They set an "equal weight" rating and a $17.00 price objective for the company. StockNews.com downgraded STAAR Surgical from a "hold" rating to a "sell" rating in a report on Thursday, February 13th. Jefferies Financial Group cut STAAR Surgical from a "buy" rating to a "hold" rating in a report on Wednesday, February 12th. Finally, Stifel Nicolaus lowered their target price on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, STAAR Surgical currently has a consensus rating of "Hold" and an average target price of $24.63.

Insider Buying and Selling at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock in a transaction dated Thursday, March 20th. The shares were acquired at an average cost of $17.96 per share, for a total transaction of $1,952,611.20. Following the transaction, the insider now directly owns 12,182,995 shares of the company's stock, valued at approximately $218,806,590.20. This trade represents a 0.90% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders have acquired 1,482,965 shares of company stock worth $24,523,688. Company insiders own 1.00% of the company's stock.

STAAR Surgical Trading Up 4.9%

Shares of STAA traded up $0.86 during trading hours on Thursday, hitting $18.29. 980,067 shares of the stock traded hands, compared to its average volume of 814,388. The business has a fifty day moving average of $17.61 and a 200-day moving average of $21.74. The firm has a market capitalization of $905.83 million, a PE ratio of -44.61 and a beta of 0.65. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $49.86.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.